By: Michael Kremer and Rachel Glennerster

"Kremer and Glennerster's aim is to find practical ways to restart research and development for these 'neglected diseases' [conditions that predominantly affect poor people in developing countries]. They believe that market and public bodies have failed to motivate research and development — only one per cent of drugs launched onto the market during the past 25 years target such diseases. They are convinced that appropriate policies and public commitment could motivate private investment in this area."

Link to Nature book review

Reference: Nature 431, 629 (2004)